Cardiovascular and Metabolic Comorbidities in Patients with Plaque-Type Psoriasis Never Treated with Systemic Antipsoriatic Drugs: a Case-Control Study

Katerina DAMEVSKA¹, Lence NELOSKA², Gjeorgji GOCEV¹, Marija MIHOVA³

1University Clinic of Dermatology, Faculty of Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia
2Public Health Center “13 Noemvri”, Skopje,
3Faculty of Computer Science and Engineering, “Ss Kiril and Metodij”, Skopje, Republic of Macedonia

*Corresponding author: Katerina Damevska, E-mail: kate_damevska@yahoo.com

UDC 616.517-036.1-052

Abstract

Previous studies have shown a higher prevalence of cardiometabolic diseases among patients with psoriasis compared to non-psoriatics. However, little attention has been paid to the effects of systemic antipsoriatic drugs. The aim of this study was to investigate the association between psoriasis and these comorbidities, comparing untreated patients with psoriasis and population-based control non-psoriatic patients.

A hospital-based case-control study included 122 patients with plaque-type psoriasis and 122 age- and gender-matched controls. Patients who ever received systemic antipsoriatic drugs were excluded.

There were no significant differences between psoriatic patients and controls regarding the prevalence of hypertension (p=0.311), coronary heart disease (p=0.480), diabetes (p=0.641), myocardial infarction (p=0.71), stroke (2.4% vs. 2.4%, p=1.00) and metabolic syndrome (p=0.764). The prevalence of hypertriglyceridemia in patients with psoriasis and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032). Furthermore, significant differences were observed in mean triglyceride levels (p=0.013). Smoking was significantly more often reported in psoriatic patients compared to controls. Patients with psoriasis also had a higher mean BMI (26.24, SD 4.42) compared with controls (24.73, SD 3.86), p=0.005. Psoriasis showed a statistically significant association with BMI obesity classification [χ²(4)=11.560, p=0.02].

The prevalence of cardiovascular and metabolic comorbidities was not significantly higher in patients with plaque-type psoriasis who were never treated with systemic antipsoriatic drugs, compared to population-based non-psoriatic controls. Our data suggest that systemic antipsoriatic drugs may play an important role in the development of these comorbidities. However, this study confirms that untreated psoriasis patients have three major modifiable increased cardiovascular risk factors, such as smoking, obesity and hypertriglyceridemia.

Key words

Psoriasis; Comorbidity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Metabolic Syndrome X; Smoking; Risk Factors

Psoriasis is a chronic, relapsing, inflammatory skin disease with an estimated prevalence worldwide ranging from 0.91% (USA) to 8.5% (Norway) (1). The most common type of psoriasis is plaque psoriasis, accounting for around 80% of cases. Approximately 20% of affected individuals have moderate-to-severe psoriasis (2). The traditional belief about psoriasis is that it is a skin disease without visceral involvement. However, by the end of the 20th century, the psoriasis model had evolved to become a disorder of the skin and joints. Nevertheless, this concept has been challenged in recent years. Currently, psoriasis is considered to be a Th1/Th17-mediated inflammatory disease, characterized by chronically elevated levels of proinflammatory cytokines (3). Recently it has been classified as an immune-mediated inflammatory disease (IMID) with high risk of systemic comorbidities (4).
Comorbidity in psoriasis has become one of the most engrossing topics in dermatology in the past five years. A mere search of the terms “psoriasis and comorbidities” in Pubmed shows more than 300 articles published over the last decade.

In 2011, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified comorbidities as one of three priority research areas in psoriasis and psoriatic arthritis (5). Traditionally, comorbidity has been defined as the presence of two or more diseases or conditions in the same individual at the same time (6). Klein et al. argue that comorbidity may occur for a variety of reasons. There is a possibility that comorbidity occurs due to the following: conjunction of independent risk factors; shared or overlapping risk factors; one disorder causes another; variable expression of one disorder; independent coincidence (7).

There is a growing evidence that psoriasis is associated with a number of systemic comorbidities, including psoriatic arthritis (PsA), obesity, hypertension, diabetes mellitus, hyperlipidemia, metabolic syndrome, cardiovascular disease (CVD), Crohn’s disease, lymphoma, malignancies and multiple sclerosis, as well as mental health comorbidity including anxiety, depression, smoking, alcoholism, and eating disorder (8-15). However, the exact mechanisms standing behind these associations are still uncertain.

The relationship between psoriasis and CVD is probably associated with the underlying chronic inflammation that exists in psoriasis, as a consequence of increased levels of proinflammatory cytokines (16). The elevated tumor necrosis factor-alpha (TNF-α) levels have been found in the skin lesions and sera of patients with psoriasis and increased serum levels have been shown to correlate with disease activity (17).

The relationship between psoriasis and associated diseases is complex, making it difficult to identify direct relationships (Figure 1). Lifestyle factors, impaired health-related quality of life, depression, and therapeutic interventions, may be confounding. Also, several biases, such as detection bias, may affect observational study results (18).

There is little information available on the effects of drugs on comorbidities. Drugs used in the treatment of psoriasis, such as acitretin, cyclosporine, and methotrexate, may adversely affect independent

---

**Figure 1.** The complex relationship between psoriasis and comorbidity [Adapted from Wakkee et al, (18)]
cardiovascular risk factors such as blood pressure and lipid levels. Methotrexate increases homocysteine levels (19), whereas cyclosporine and acitretin induce hyperlipidemia (20). Thus, high prevalence of some comorbidities in patients with psoriasis may be, at least partly, due to systemic antipsoriatic drugs. Wakkee at al. argue that effects of systemic drugs on the cardiovascular risk represent a sum of anti-inflammatory effects and atherogenic side effects (18).

The objective of this study was to determine the prevalence of comorbidities in patients with psoriasis never treated with any systemic antipsoriatic drugs.

**Methods**

**Severity of psoriasis**
The severity of psoriasis was assessed using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA). A PASI score ≤10 defines psoriasis as mild, whereas scores above 10 classify it as moderate or severe. Patients were classified in regard to the age of onset of psoriasis; type 1: onset before the age of 40 years, and type 2: onset after the age of 40 years (22). The diagnosis of psoriatic arthritis (PsA) was made using Moll and Wright criteria (23).

**Comorbidity data**
A list of clinically-relevant comorbidities was derived from diagnoses included in the Charlson Comorbidity Index (21). Chronic conditions were classified using diagnoses at discharge or drug prescriptions, for example: diabetes - if use of antidiabetic drugs was registered; hypertension - if BP ≥140/90 mmHg was found, and/or current use of an antihypertensive.

**Metabolic syndrome**
Metabolic syndrome was diagnosed by the presence of three or more of the following criteria of the National Cholesterol Education Programme’s Adult Treatment Panel III (ATP III): waist circumference > 102 cm in men and > 88 cm in women; hypertriglyceridemia > 1.7 mmol/l (150 mg/dl) or ongoing drug treatment for elevated triglycerides; high density lipoprotein (HDL) cholesterol < 1.0 mmol/l (40 mg/dl) in men and < 1.3 mmol/dl (50 mg/dl) in women or ongoing antilipidemic treatment; blood pressure > 130/85 mmHg, or ongoing antihypertensive treatment; fasting plasma glucose > 6.1 mmol/l (100 mg/dl) or ongoing antidiabetic treatment (24).

**Body mass index**
The body mass index (BMI) was calculated as weight in kilograms divided by height in meters² and patients were classified as underweight (<18.5 kg/m²), normal (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), and obese (≥30.0 kg/m²).
Blood pressure
Blood pressure (BP) was measured in sitting position using a standard mercury sphygmomanometer.

Smoking
Smoking habit was classified into two categories of never smokers and ex-smokers/current smokers.

Alcohol consumption
Alcohol consumption was classified into two categories of none/low/moderate: up to three alcoholic drinks per week, and regular/heavy: ≥ 4 alcoholic drinks per week.

Statistical analysis
Categorical variables were expressed as frequencies and percentages, and numerical variables as means, range and standard deviations (SD). Odds ratios (OR) were estimated using logistic regression models with conditional 95% confidence intervals (CI). The proportion of comorbidities in psoriatic patients was compared with their matched non-psoriatic controls. Comparisons were made by using the Student’s t-test for parametric continuous variables, Mann-Whitney U test for nonparametric continuous variables and Chi-square test for qualitative variables. The limit for statistical significance was set at \( p \leq 0.05 \). The SPSS version 10 statistical software (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis.

Results
Baseline characteristics of the study group are shown in Table 1. One hundred and twenty-two patients with psoriasis (52 male and 70 female, the mean age 51.52 years, SD 15.56, range 19 - 80 years), and 122 age- and gender-matched controls (52 males and 70 females, the mean age 51.98; years, SD 15.72, range 19 - 79 years, participated in the study. Figure 2 shows their age and sex distribution. A close match between the groups can be seen. No statistically significant difference was noted in the mean age and sex ratio between the groups (\( p=0.82 \) and \( p=1.00 \), respectively).

Disease characteristics
Type 1 psoriasis was found in 78 patients (63.9%). The mean age of psoriasis onset was 33.34 years (SD 17.14, range 1 - 76). The mean duration of psoriasis was 17.9 years (SD14.21, range 1 - 65 years). Psoriatic arthritis was present in 16 patients (13.1%). The mean age of PsA onset was 39.2 years (range 27 - 59). The mean interval between the onset of psoriasis and onset of PsA was 6.67 years (SD 6.6). In 2 patients, arthritis developed before psoriasis was diagnosed. A positive family history of psoriasis was reported by 21 patients (17.21%), with a 92% incidence in first-degree relatives.

PASI scores ranged from 2.4 to 62.0 (mean 14.75, SD 12.78) and 56 patients (45.9%) had moderate to severe psoriasis (PASI>10). BSA ranged

Figure 2. Age and sex distribution of patients with plaque psoriasis and controls
from 2% to 85% (mean 15.23, SD 13.09), while 55 (45.1%) patients had > 10% of body surface area involved. Figure 3 shows distribution of patients according to the PASI score.

The prevalence of cardiovascular and metabolic comorbid conditions
There were no significant differences in the prevalence of hypertension (29.5% vs. 23.7%, p=0.311), coronary heart disease (13.9% vs. 17.2%, p=0.480), diabetes (9.0% vs. 7.3%, p=0.641), myocardial infarction (3.2% vs. 2.4%, p=0.71), stroke (2.4% vs. 2.4%, p=1.00) and metabolic syndrome (24.6% vs. 22.9%, p=0.764), between cases and controls (Table 2), (Figure 4).

The prevalence of hypertriglyceridemia in patients with psoriasis and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032) (Table 2), (Figure 4). Furthermore, a significant difference was found in mean triglyceride levels of patients and controls (170.19±67.84 mg/dL vs. 149.27±81.15 mg/dL, p=0.013).

Lifestyle factors
Smoking was significantly more prevalent in psoriasis patients compared to controls (58.1% vs. 44.2%, OR 1.813, 95% CI 1.04-3.04, p=0.032) (Table 1).

Regular and heavy alcohol consumption was infrequent and of similar prevalence in psoriasis cases and controls: 20.5% vs. 17.2%, p=0.513 (Table 1).

Patients with psoriasis had a higher mean BMI (26.24, SD 4.42) compared to controls (24.73, SD 3.86), p=0.005 (Table 1), (Figure 5). Furthermore, psoriasis showed a statistically significant association with BMI obesity classification [$\chi^2(4)=11.560$, p=0.02].

Discussion
Psoriasis and cardiovascular risk
The relationship between psoriasis and increased risk of CVD remains controversial (25). In general, most of the previous studies suggest that people with psoriasis are at increased risk of CVD (8-10, 16, 20, 26-28). This was not confirmed in a large prospective cohort study conducted by Stern and Lange (29). Furthermore, two recent studies of general population (30, 31) demonstrated that the relationship between psoriasis and cardiovascular risk (CVR) is insignificant, and that traditional cardiovascular risk factors are significantly associated with cardiovascular risk in psoriasis (30, 31). Moreover, two population-based database studies that included pharmaceutical data did not confirm the association between psoriasis and treatment of CVD (32, 33). Mallbris et al. found a 50% greater risk of death from CVD among psoriatic inpatients, compared with the general population. In contrast, the overall risk of cardiovascular death was slightly decreased among outpatients with psoriasis (27).

A recent meta-analysis of cardiovascular risk confirms that psoriasis is related with an increased risk of cardiovascular mortality (28). However, it remains unclear whether cardiovascular risk in
Our study showed no significant difference in the prevalence of coronary heart disease (CHD) (p=0.48), hypertension (p=0.31), myocardial infarction (p=0.71), stroke (p=1) and metabolic syndrome (p=0.76), between patients with psoriasis and controls.

Psoriasis and diabetes
In recent years it has been recognized that patients with psoriasis carry an increased risk of type 2 diabetes. Two meta-analyses have examined diabetes in psoriatic patients. Armstrong et al. conducted a meta-analysis of 27 observational studies and found that psoriasis is associated with a relative risk of 1.27 (95% CI 1.16

Table 1. Baseline characteristics of the study group

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Psoriatics (n=122)</th>
<th>Controls (n=122)</th>
<th>OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD), years</td>
<td>51.52 (15.56)</td>
<td>51.98 (15.72)</td>
<td>NA</td>
<td>0.82</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>52/70</td>
<td>52/70</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>Smoking habit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current +ex-smoker, n (%)</td>
<td>51+21=72 (58.1)</td>
<td>42+12=54(44.2)</td>
<td>1.81 (1.09-3.01)</td>
<td>0.021</td>
</tr>
<tr>
<td>Never smoker</td>
<td>50 (41.8)</td>
<td>68 (55.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol consumption, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>97 (79.5)</td>
<td>101 (82.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular/heavy</td>
<td>25 (20.5)</td>
<td>21 (17.2)</td>
<td>1.24 (0.65-2.35)</td>
<td>0.513</td>
</tr>
<tr>
<td>BMI obesity classification n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>4 (3.3)</td>
<td>5 (4.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>49 (40.2)</td>
<td>74 (60.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>44 (36.1)</td>
<td>29 (23.8)</td>
<td>NA</td>
<td>0.02</td>
</tr>
<tr>
<td>Obese</td>
<td>20 (16.4)</td>
<td>12 (9.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe obesity</td>
<td>5 (4.1)</td>
<td>2 (1.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, mean (SD), kg</td>
<td>26.24 (4.42)</td>
<td>24.73 (3.86)</td>
<td>NA</td>
<td>0.005</td>
</tr>
</tbody>
</table>

SD - standard deviation; OR - odds ratio; NA - not applicable; BMI - body mass index

Psoriasis is increased beyond that conferred by traditional cardiovascular risk factors. Samarasekera et al. evaluated 15 cohorts and meta-analyses of the magnitude of CVD risk for the primary outcomes of CVD mortality, stroke and myocardial infarction and identified increased CVD risk only in people with severe psoriasis (defined as requiring systemic therapy or hospital admission). They detected that majority of studies failed to adequately adjust for key traditional risk factors (25).

In this matched case-control study, we found no differences between subjects with and without psoriasis, in regard to cardiovascular disease and major cardiovascular risk (CVR) factors.
up study with a nested case-control analysis within the UK-based General Practice Research Database. They found that the risk of incident DM increased with psoriasis duration and severity (37). It is well known that chronic systemic inflammation of psoriasis induces endothelial dysfunction, altered glucose metabolism, and insulin resistance which all together play a significant role in the development of obesity, diabetes mellitus, dyslipidemia, and cardiovascular disease (38). It is also possible that patients with psoriasis use topical corticosteroids for long periods of time, which are systemically absorbed and contribute to the development of diabetes (37, 39). However, several studies, failed to establish such a relationship - 1.40) for developing diabetes (34). Findings from a meta-analysis conducted by Cheng et al. suggested that individuals with psoriasis may have a slightly increased risk of diabetes (OR 1.42, 95% CI 1.40 - 1.45) (35). A cross-sectional study of Shapiro et al. performed using a database of a large health provider in Israel, showed that the incidence of diabetes was significantly higher in psoriasis patients in comparison with the control group (OR 1.27, 95% CI 1.1 - 1.48) (36). Interestingly, authors found an association between diabetes and multiple use of very potent topical steroids (P < 0.05) or systemic medications for psoriasis (methotrexate, cyclosporine or acitretin) (P < 0.001) (36). Brauchli et al. conducted a follow-up study with a nested case-control analysis within the UK-based General Practice Research Database. They found that the risk of incident DM increased with psoriasis duration and severity (37). It is well known that chronic systemic inflammation of psoriasis induces endothelial dysfunction, altered glucose metabolism, and insulin resistance which all together play a significant role in the development of obesity, diabetes mellitus, dyslipidemia, and cardiovascular disease (38). It is also possible that patients with psoriasis use topical corticosteroids for long periods of time, which are systemically absorbed and contribute to the development of diabetes (37, 39). However, several studies, failed to establish such a relationship

<table>
<thead>
<tr>
<th></th>
<th>Psoriatics N=122</th>
<th>Controls N=122</th>
<th>OR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>36 (29.5)</td>
<td>29 (23.7)</td>
<td>1.342</td>
<td>0.759-2.374</td>
<td>p=0.311</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=1.029</td>
</tr>
<tr>
<td>Diabetes</td>
<td>11 (9.0)</td>
<td>9 (7.3)</td>
<td>1.244</td>
<td>0.496-3.119</td>
<td>p=0.641</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=0.218</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>17 (13.9)</td>
<td>21 (17.2)</td>
<td>0.779</td>
<td>0.388-1.561</td>
<td>p=0.480</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=0.499</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>4 (3.2)</td>
<td>3 (2.4)</td>
<td>1.345</td>
<td>0.295-6.138</td>
<td>p=0.71</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=0.147</td>
</tr>
<tr>
<td>Metabolic syndrome, n (%)</td>
<td>30 (24.6)</td>
<td>28 (22.9)</td>
<td>1.09</td>
<td>0.61-1.97</td>
<td>p=0.764</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=0.090</td>
</tr>
<tr>
<td>Stroke</td>
<td>3 (2.4)</td>
<td>3 (2.4)</td>
<td>1.0</td>
<td>0.198-5.055</td>
<td>p=1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>χ²=0.0</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↑TG</td>
<td>51 (41.8)</td>
<td>35 (28.7)</td>
<td>1.78</td>
<td>1.04-3.04</td>
<td>0.032</td>
</tr>
<tr>
<td>↓HDL-C</td>
<td>37 (30.3)</td>
<td>31 (25.4)</td>
<td>1.27</td>
<td>0.73-2.24</td>
<td>0.392</td>
</tr>
</tbody>
</table>

TG - Triglyceridemia > 1.7 mmol/L; HDL-C - high-density lipoprotein cholesterol < 1.0 mmol/L (Male) or < 1.3 mmol/L (Female)
Traditional systemic therapies for psoriasis may aggravate cardiovascular risk factors (19, 20). Thus, high prevalence of CVD may be in part due to systemic antipsoriatic therapy. It is rather difficult to assess the independent contribution of systemic antipsoriatic drugs on the development of CVR in patients with psoriasis, since a certain number of concurrent factors, such as lifestyle factors, as well as other systemic drugs such as NSAIL, antidepressants and diuretics, needs to be taken into consideration, as these drugs are widely prescribed for patients with psoriasis (47).

Psoriasis and traditional cardiovascular risk factors

Our study confirms that psoriasis patients have three lifestyle/classic risk factors for CVD more frequently compared to controls: smoking, obesity and hypertriglyceridemia. The prevalence of smoking was higher in patients with psoriasis (41.8%) than in the control group (34.4%), and higher than in general population in Macedonia (35%) (48). Psoriasis showed a statistically significant association with BMI and obesity classification. This finding is in agreement with most of the previously published studies.

The major weakness of our study is its sample size, while its strength is its matched case-control design which controlled fundamental confounders of age and gender. Besides, both case and control subjects were selected from the same source population. All data

Figure 4. Prevalence of comorbid conditions in patients with plaque psoriasis and controls

HTA - hypertension; DM - diabetes mellitus; CVD - cardiovascular diseases; MI - myocardial infarction; MetS - metabolic syndrome, CVI - cerebrovascular insult; TG - Triglyceridemia > 1.7 mmol/L; HDL-C - high-density lipoprotein cholesterol < 1.0 mmol/L (Male) or < 1.3 mmol/L (Female)
were collected through interviews and measurements of disease activity were performed by an experienced dermatologist.

**Conclusion**

In conclusion, our data suggest that systemic antipsoriatic drugs may exert an important influence on the prevalence of cardiometabolic comorbidity in patients with psoriasis. Furthermore, our study confirms that untreated psoriatic patients have three major increased lifestyle cardiovascular risk factors: smoking, obesity and hypertrigliceridemia. Further research will explore the effects of systemic antipsoriatic drugs on these comorbid conditions in psoriasis.

**References**


**Figure 5.** BMI obesity classification among patients with plaque psoriasis and control group


Uvod: Komorbiditeti su bolesti koje koegzistiraju sa bolešću koja je cilj ispitivanja; u ovom radu to je psorijaza. Sve su brojniji radovi u svetskoj literaturi koji doprinose stavu da je psorijaza značajno povezana sa nizom komorbiditeta kao što su psoriatični arthritis, deblijina, hipertenzija, dijabetes, hiperlipidemija, metabolički sindrom, kardiovaskularne bolesti (KVB), Kronova bolest, limfomi, neoplazije i multipla skleroza, kao i anksioznost, alkoholizam, pušenje i neravnoteža u ishrani. Nije poznat tačan mehanizam odgovaran za ovu udruženost ali se ne može zanemariti direktni uticaj hronične inflamacije i povećani nivo TNF-α. Niz drugih faktora utiču na tu asocijaciju (Shema 1). Malo je radova koji se odnose na uticaj lekova na komorbiditet kojih se nisu lečen sistemska terapija psorijaze. Rezultati: Demografske i osnovne karakteristike ispitivane populacije su prikazane u tabeli 1. Sve su brojniji radovi u svetskoj literaturi koji doprinose stavu da je psorijaza značajno povezana sa nizom komorbiditeta kao što su psoriatični arthritis, deblijina, hipertenzija, dijabetes, hiperlipidemija, metabolički sindrom, kardiovaskularne bolesti (KVB), Kronova bolest, limfomi, neoplazije i multipla skleroza, kao i anksioznost, alkoholizam, pušenje i neravnoteža u ishrani. Nije poznat tačan mehanizam odgovaran za ovu udruženost ali se ne može zanemariti direktni uticaj hronične inflamacije i povećani nivo TNF-α. Niz drugih faktora utiču na tu asocijaciju (Shema 1). Malo je radova koji se odnose na uticaj lekova na komorbiditet, ali je dobro poznato da metotreksat povećava vrednosti homocisteina u serumu, a siklosporin i acitretin uzrokuju povišeni krvni pritisak i hiperlipidemiju. Cilj: Ovo istraživanje je obavljeno sa ciljem procene prevalencije kardiovaskularnih i metaboličkih komorbidnih stanja kod bolesnika sa plak-tipom psorijaze koje nikada nisu dobijale sistemsku terapiju za psorijazu: analitička studija slučaja po polu i uzrastu omogućilo je eliminaciju uticaja ovih kovarijabilna na rezultate istraživanja. Rezultati: Demografske i osnovne karakteristike ispitivane populacije su prikazane u tabeli 1. Sve su brojniji radovi u svetskoj literaturi koji doprinose stavu da je psorijaza značajno povezana sa nizom komorbiditeta kao što su psoriatični arthritis, deblijina, hipertenzija, dijabetes, hiperlipidemija, metabolički sindrom, kardiovaskularne bolesti (KVB), Kronova bolest, limfomi, neoplazije i multipla skleroza, kao i anksioznost, alkoholizam, pušenje i neravnoteža u ishrani. Nije poznat tačan mehanizam odgovaran za ovu udruženost ali se ne može zanemariti direktni uticaj hronične inflamacije i povećani nivo TNF-α. Niz drugih faktora utiču na tu asocijaciju (Shema 1). Malo je radova koji se odnose na uticaj lekova na komorbiditet, ali je dobro poznato da metotreksat povećava vrednosti homocisteina u serumu, a siklosporin i acitretin uzrokuju povišeni krvni pritisak i hiperlipidemiju. Cilj: Ovo istraživanje je obavljeno sa ciljem procene prevalencije kardiovaskularnih i metaboličkih komorbidnih stanja kod bolesnika sa plak-tipom psorijaza koji nikada nisu dobijali antipsorijatici za sistemsku terapiju. Istraživanje je sprovedeno kao studija slučaja - kontrola, a uparivanje kontrolne grupe

Kardiovaskularni ili metabolički komorbiditet kod osoba sa plak-tipom psorijaze koje nikada nisu dobijale sistemska terapiju za psorijazu: analitička studija slučaja

Sažetak

Uvod: Komorbiditeti su bolesti koje koegzistiraju sa bolešću koja je cilj ispitivanja; u ovom radu to je psorijaza. Sve su brojniji radovi u svetskoj literaturi koji doprinose stavu da je psorijaza značajno povezana sa nizom komorbiditeta kao što su psoriatični arthritis, deblijina, hipertenzija, dijabetes, hiperlipidemija, metabolički sindrom, kardiovaskularne bolesti (KVB), Kronova bolest, limfomi, neoplazije i multipla skleroza, kao i anksioznost, alkoholizam, pušenje i neravnoteža u ishrani. Nije poznat tačan mehanizam odgovaran za ovu udruženost ali se ne može zanemariti direktni uticaj hronične inflamacije i povećani nivo TNF-α. Niz drugih faktora utiču na tu asocijaciju (Shema 1). Malo je radova koji se odnose na uticaj lekova na komorbiditet, ali je dobro poznato da metotreksat povećava vrednosti homocisteina u serumu, a siklosporin i acitretin uzrokuju povišeni krvni pritisak i hiperlipidemiju. Cilj: Ovo istraživanje je obavljeno sa ciljem procene prevalencije kardiovaskularnih i metaboličkih komorbidnih stanja kod bolesnika sa plak-tipom psorijaza koji nikada nisu dobijali antipsorijatici za sistemsku terapiju. Istraživanje je sprovedeno kao studija slučaja - kontrola, a uparivanje kontrolne grupe

Program
ATP III - Adult Treatment Panel III
HDL - high density lipoprotein
SD - standard deviations
OR - odds ratios
CI - confidence intervals
PsA - psoriatic arthritis
CVR - cardiovascular risk
CHD - coronary heart disease
NA - not applicable
TG - triglyceridemia
MI - myocardial infarction
MetS - metabolic syndrome
CVI - cerebrovascular insult

Abbreviations
IMID - immune-mediated inflammatory disease
CVD - cardiovascular disease
TNF-α - tumor necrosis factor-alpha
UV - ultraviolet rays
GP - general practitioner
BMI - body mass index
BP - blood pressure
PASI - Psoriasis Area and Severity Index
BSA - body surface area
NCEP - National Cholesterol Education Program

© 2009 The Serbian Association of Dermatovenereologists
Zaključak: Istraživanje je pokazalo da pacijenti sa plak psorijazom koji nikada nisu lečeni od psorijaze sistemskim lekovima nemaju statistički značajno češću pojavu kardiovaskularnih i metaboličkih komorbidnih stanja u odnosu na kontrolnu grupu. Sistemska antipsorijatični lekovi mogu uticati na pojavu ovih komorbiditeta. Ipak, ova studija je pokazala da bolesnici sa psorijazom imaju povišena tri važna faktora rizika za nastanak kardiovaskularnih bolesti − pušenje, debljinu i hipertrigliceridemiju.

Ključne reči
Psorijaza; Komorbiditet; Kardiovaskularne bolesti; Dijabetes melitus tip 2; Metabolički sindrom X; Pušenje; Faktori Rizika